UCB IL-17A/F dual inhibitor starts phase 3 clinical trials in China

Source: Guanlan Pharmaceutical

The Chinese drug clinical trial registration and information disclosure platform shows that UCB (UCB) has launched a single-arm, international multi-center phase 3 clinical trial of bimekizumab in China for the treatment of active axial spondylitis and ankylosing spine Patients with axial spondyloarthritis with negative inflammation and radiology.

Screenshot source: Chinadrugtrials

Public information shows that bimekizumab is a fully humanized monoclonal antibody that can strongly and specifically neutralize IL-17A and IL-17F.

The launch of Utimes in China is a phase 3, international multi-center, open-ended extension study, which aims to evaluate the treatment of bimekizumab in the treatment of active axial spondylitis, ankylosing spondylitis and radiology-negative axial spine Long-term safety, tolerability and efficacy of arthritis participants.

According to the information on the drug clinical trial registration and information disclosure platform, this is the fourth clinical study of bimekizumab registered in China.

According to a press release issued by Utimer, bimekizumab has obtained positive results in a phase 2b clinical trial for the treatment of ankylosing spondylitis (AS).

Note: The original text has been deleted